Welcome to our dedicated page for iSpecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on iSpecimen stock.
iSpecimen Inc., headquartered in Lexington, MA, is a leading marketplace for human biospecimens. The company provides researchers with the specimens they need from the patients they want through its innovative iSpecimen Marketplace. This online platform connects healthcare organizations with access to patients and specimens with scientists in need of these vital resources.
Utilizing proprietary, cloud-based technology, iSpecimen enables researchers to intuitively search for specimens across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. This system allows for easy and compliant access to specimens, facilitating scientific discovery and advancing healthcare for all.
iSpecimen stands out by offering a unique value proposition to both researchers and partner sites. Researchers gain the necessary resources to drive their studies, while partner sites can contribute to biomedical discovery and benefit financially. The company caters to a global market, with operations spanning the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority of its revenue coming from the Americas.
In recent news, iSpecimen has achieved a sequential quarterly revenue growth of 75%, driven by enhanced operational efficiencies and new business initiatives. The company continues to expand its network by adding new suppliers and reinforcing existing relationships to provide researchers with increased access to highly sought-after biospecimens, especially for oncology research. Additionally, iSpecimen is making strides in quality control and assurance through digital AI histopathology services, enhancing data quality and operational efficiency.
For investors and media inquiries, iSpecimen's contacts at KCSA Strategic Communications are available for further information.
iSpecimen Inc. (Nasdaq: ISPC) announced an expansion of its human biospecimen supplier network to enhance the availability of whole blood, plasma, and biofluids for liquid biopsy development. This move aims to support a growing market projected to reach $1.45 billion with a 24% annual growth rate through 2026. The company has supplied thousands of biospecimens for nearly 30 studies, reinforcing its commitment to advancing liquid biopsy technology, which offers less invasive disease detection methods.
iSpecimen Inc. (Nasdaq: ISPC) announced its inclusion in the Russell Microcap Index, effective September 20, 2021. This inclusion signifies recognition of the company's growth in the biospecimen procurement sector, expected to enhance visibility within the investment community. Being part of the Russell indexes, which benchmark approximately $10.6 trillion in assets, positions iSpecimen favorably for attracting institutional investors. The company is also refining its iSpecimen Marketplace, aiming to support researchers in scientific discovery.
iSpecimen (Nasdaq: ISPC), a leader in the online marketplace for human biospecimens, announced CEO Christopher Ianelli will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. His presentation will be available on-demand starting September 13 at 7:00 a.m. ET. iSpecimen connects life scientists with healthcare providers through its innovative platform to facilitate medical discovery.
iSpecimen Inc. (ISPC) announced a growth in its cancer-related supplier network despite challenges posed by COVID-19. The company formed partnerships with various labs and biobanks, significantly enhancing access to tissue and biofluid specimens from cancer patients. A recent collaboration with a European healthcare organization adds 17 types of cancer specimens, expanding the network to over 30 suppliers. These developments are aimed at improving specimen availability for cancer research, supporting advancements in therapies and diagnostics.
iSpecimen Inc. (Nasdaq: ISPC) announced that CEO Dr. Christopher Ianelli will be interviewed on The RedChip Money Report® on Bloomberg TV, airing at 7 p.m. ET on August 14, 2021. This program reaches approximately 73 million homes in the U.S. and offers insights on small-cap investing and interviews with industry leaders. The company provides an online marketplace for human biospecimens, linking life scientists with healthcare providers through its cloud-based technology. More details are available at www.ispecimen.com.
iSpecimen Inc. (ISPC) reported a 93% revenue growth year-over-year, reaching $2.9 million for Q2 2021. The company completed its IPO, raising approximately $18.2 million in net proceeds. It also expanded its registered research users by 40%, totaling over 3,800. However, iSpecimen experienced a net loss of approximately $1.4 million, attributed to increased operating expenses post-IPO. The company aims to enhance its marketplace capabilities while addressing rising costs from specimen procurement.
iSpecimen (Nasdaq: ISPC) has enhanced its custom biofluids collection service to deliver urgently needed research samples faster to life sciences organizations. Originally developed during COVID-19, this service allows researchers, particularly in the Boston area, to receive direct blood draws and saliva samples within hours. CEO Christopher Ianelli emphasized that this service aims to meet ongoing demands for fresh specimens, thus supporting medical research effectively. Additionally, iSpecimen invites Boston-area individuals to donate biospecimens for research purposes.
iSpecimen Inc. (Nasdaq: ISPC) will report its financial results for the second quarter ending June 30, 2021, before market open on August 10, 2021. A conference call and audio webcast will take place at 8:30 a.m. Eastern Time the same day, featuring remarks from CEO Christopher Ianelli, CFO Tracy Curley, and COO Jill Mullan. Those unable to attend can access a replay until August 24, 2021. iSpecimen operates an online marketplace for human biospecimens, connecting researchers with healthcare providers.
On July 1, 2021, iSpecimen (Nasdaq: ISPC) announced the closing of an additional 337,500 shares of common stock due to the full exercise of the underwriters' over-allotment option in its initial public offering (IPO). The shares were sold at $8.00 each, raising $2.7 million and increasing the total gross proceeds of the IPO to $20.7 million. iSpecimen's shares began trading on June 17, 2021. ThinkEquity managed the IPO, and a registration statement was effective as of June 16, 2021.
iSpecimen has successfully closed its initial public offering (IPO) of 2,250,000 shares at $8.00 per share, generating $18 million in gross proceeds. The shares began trading on the Nasdaq Capital Market under the ticker ISPC on June 17, 2021. This offering was managed by ThinkEquity, a division of Fordham Financial Management. The funds raised will support the company's online marketplace connecting life scientists with healthcare providers for biospecimens, enhancing medical discovery capabilities.
FAQ
What is the current stock price of iSpecimen (ISPC)?
What is the market cap of iSpecimen (ISPC)?
What is iSpecimen Inc.?
Where is iSpecimen Inc. headquartered?
How does the iSpecimen Marketplace work?
What kind of specimens does iSpecimen provide?
What recent achievements has iSpecimen made?
Who can benefit from using iSpecimen's services?
What regions does iSpecimen operate in?
How can researchers access iSpecimen's services?
How does iSpecimen ensure quality control?
How can investors get in touch with iSpecimen?
